Protective effects of grape seed proanthocyanidin extracts on cerebral cortex of streptozotocin-induced diabetic rats through modulating AGEs/RAGE/NF-κB pathway

Journal of Nutritional Science and Vitaminology

Volumn 56, Issue 2, 2010, Pages 87-97

  Lu, Mei ^a,b   Xu, Ling ^a,b   Li, Baoying ^a,b   Zhang, Weidong ^c   Zhang, Chengmei ^d   Feng, Hong ^a,b   Cui, Xiaopei ^a,b   Gao, Haiqing ^a,b  

^a Key Laboratory of Cardiovascular Proteomics of Shandong Province   (China)

^b SHANDONG UNIVERSITY   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^d SHANDONG UNIVERSITY   (China)

Author keywords

Advanced glycation end products; Cerebral cortex; Diabetic encephalopathy; Grape seed proanthocyanidin extracts; Nuclear factor kappa B p65

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; GRAPE SEED EXTRACT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; PROANTHOCYANIDIN DERIVATIVE; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BRAIN CORTEX; CONTROLLED STUDY; DIABETIC NEUROPATHY; DRUG EFFECT; DRUG MECHANISM; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PROTEIN EXPRESSION; PYRAMIDAL NERVE CELL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; TREATMENT OUTCOME; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTIOXIDANTS; BLOTTING, WESTERN; BODY WEIGHT; BRAIN DISEASES, METABOLIC; CEREBRAL CORTEX; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; GLYCOSYLATION END PRODUCTS, ADVANCED; GRAPE SEED EXTRACT; INTERCELLULAR ADHESION MOLECULE-1; MALE; NF-KAPPA B; OXIDATIVE STRESS; PROANTHOCYANIDINS; RATS; RATS, WISTAR; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STREPTOZOCIN; VASCULAR CELL ADHESION MOLECULE-1;

RATTUS; VITACEAE;

EID: 77954296915     PISSN: 03014800     EISSN: 18817742     Source Type: Journal    
DOI: 10.3177/jnsv.56.87     Document Type: Article

References (40)

1. Mijnhout GS, Scheltens P, Diamant M. 2006. Diabeticencephalopathy: A concept in need of a definition. Dia-betologia 49: 1447-1448.
2. Aragno M, Mastrocola R, Medana C. 2005. Up-regula-tion of advanced glycated products receptors in thebrain of diabetic rats is prevented by antioxidant treat-ment. Endocrinology 146: 5561-5567.
3. Bierhaus A, Humpert PM, Morcos M. 2005. Under-standing RAGE, the receptor for advanced glycation endproducts. J Mol Med 83: 876-886.
4. van den Berg E, Kessels RP, Kappelle LJ. 2006. Type 2diabetes, cognitive function and dementia: vascular andmetabolic determinants. Drugs Today 42: 741-754.
5. Katz J, Bhattacharyya I, Farkhondeh-Kish F. 2005.Expression of the receptor of advanced glycation endproducts in gingival tissues of type 2 diabetes patientswith chronic periodontal disease: a study utilizingimmunohistochemistry and RT-PCR. J Clin Periodontol32: 40-44.
6. Ziyadeh FN, Cohen MP, Guo J, Jin Y. 1997. RAGE mRNAexpression in the diabetic mouse kidney. Mol Cell Bio-chem 170: 147-152.
7. Park IH, Yeon SI, Youn JH. 2004. Expression of a novelsecreted splice variant of the receptor for advanced gly-cation end products (RAGE) in human brain astrocytesand peripheral blood mononuclear cells. Mol Immunol40: 1203-1211.
8. Schmidt AM, Yan SD, Yan SF, Stern DM. 2000. The biol-ogy of the receptor for advanced glycation end productsand its ligands. Biochim Biophys Acta 1498: 99-111.
9. Haslbeck KM, Schleicher E, Bierhaus A. 2005. TheAGE/RAGE/NF-(kappa)B pathway may contribute tothe pathogenesis of polyneuropathy in impaired glucosetolerance (IGT). Exp Clin Endocrinol Diabetes 113: 288-291.
10. Sasaki N, Toki S, Chowei H. 2001. Immunohistochemi-cal distribution of the receptor for advanced glycationend products in neurons and astrocytes in Alzheimer'sdisease. Brain Res 888: 256-262.
11. Ramasamy R, Vannucci SJ, Yan SS. 2005. Advancedglycation end products and RAGE: a common thread inaging, diabetes, neurodegeneration, and inflammation.Glycobiology 15:16R-28R
12. Liu YN, Shen XN, Yao GY. 2006. Effects of grape seed proanthocyanidins extracts on experimental diabetic nephropathy in rats. Wei Sheng Yan Jiu 35: 703-705
13. Yamakoshi J, Saito M, Kataoka S. 2002. Safety evalua-tion of proanthocyanidin-rich extract from grape seeds.Food Chem Toxicol 40: 599-607.
14. Pataki T, Bak I, Kovacs P. 2002. Grape seed proanthocy-anidins improved cardiac recovery during reperfusionafter ischemia in isolated rat hearts. Am J Clin Nutr 75:894-899.
15. Sano T, Oda E, Yamashita T. 2005. Anti-thromboticeffect of proanthocyanidin, a purified ingredient ofgrape seed. Thromb Res 115: 115-121.
16. Hu M, McClements DJ, Decker EA. 2004. Antioxidantactivity of a proanthocyanidin-rich extract from grapeseed in whey protein isolate stabilized algae oil-in-wateremulsions. J Agric Food Chem 52: 5272-5276.
17. Natella F, Belelli F, Gentili V. 2002. Grape seed proantho-cyanidins prevent plasma postprandial oxidative stressin humans. J Agric Food Chem 50: 7720-7725.
18. Kim H, Deshane J, Barnes S, Meleth S. 2006. Proteomics analysis of the actions of grape seed extract in rat brain the technological and biological implications for the study Diabetesof the actions of psychoactive compounds. Life Sci 78: 2060-2065.
19. Shao ZH, Becker LB, Vanden Hoek TL. 2003. Grape seed aging in very old men with type 2 diabetes: the Hono-proanthocyanidin extract attenuates oxidant injury in lulu-Asia Aging Study. Diabetes Care 29: 2268-2274.cardiomyocytes. Pharmacol Res 47: 463-469.
20. Pinent M, Blay M, Blade MC. 2004. Grape seed-derived procyanidins have an antihyperglycemic effect in streptozotocin-induced diabetic rats and insulinomimetic activity in insulin-sensitive cell lines. Endocrinology 145: 4985-4990.
21. Zhang FL, Gao HQ, Wu JM. 2006. Selective inhibition by grape seed proanthocyanidin extracts of cell adhesion molecule expression induced by advanced glycation end products in endothelial cells. J Cardiovasc Pharm 48: 47-53.
22. Xu L, Li B, Cheng M. 2008. Oral administration of grape seed proanthocyanidin extracts downregulate RAGE dependant nuclear factor-kappa B p65 expression in the hippocampus of streptozotocin induced diabetic rats. Exp Clin Endocrinol Diabetes 116: 215-224.
23. Biessels GJ, Kerssen A, de Haan EH, Kappelle LJ. 2007. Cognitive dysfunction and diabetes: implications for primary care. Primary Care Diabetes 1: 187-193
24. van den Berg E, Kessels RP, Kappelle LJ. 2007. Type 2 diabetes, cognitive function and dementia: vascular and metabolic determinants. TTMed 11: E7.
25. Sima AA, Kamiya H, Li ZG. 2004. Insulin, C-peptide, hyperglycemia, and central nervous system complications in diabetes. Eur J Pharmacol 490: 187-197.
26. Brands AM, Henselmans JM, de Haan EH, Biessels GJ. 2003. Diabetic encephalopathy: an underexposed complication of diabetes mellitus. Ned Tijdschr Geneeskd 147: 11-14.
27. Akisaki T, Sakurai T, Takata T. 2006. Cognitive dysfunction associates with white matter hyperintensities and subcortical atrophy on magnetic resonance imaging of the elderly diabetes mellitus Japanese elderly diabetes intervention trial (J-EDIT). Diabetes Metab Res Rev 22: 376-384.
28. Sima AA. 2006. Pathological mechanisms involved in diabetic neuropathy: can we slow the process? Curr Opin Invest Drugs 7: 324-337.
29. Suzuki Y, Hata T, Miyaoka H. 1996. Diabetes with the 3243 mitochondrial tRNALeu(UUR) mutation. Diabetes Care 19: 739-743.
30. Korf ES, White LR, Scheltens P, Launer LJ. 2006. Brain aging in very old men with type 2 diabetes: the Honolulu-Asia Aging Study. Diabetes Care 29: 2268-2274.
31. Wada R, Yagihashi S. 2005. Role of advanced glycation end products and their receptors in development of diabetic neuropathy. Ann NY Acad Sci 1043: 598-604.
32. Kouta Y, Sakurai T, Yokono K. 2006. Cognitive dysfunction and dementia associated with elderly diabetes. Nippon Rinsho 64: 119-123.
33. Haslbeck KM, Neundorfer B, Schlotzer-Schrehardtt U. 2007. Activation of the RAGE pathway: a general mechanism in the pathogenesis of polyneuropathies? Neurol Res 29: 103-110.
34. Haslbeck KM, Bierhaus A, Erwin S. 2004. Receptor for advanced glycation endproduct (RAGE)-mediated nuclear factor-kappaB activation in vasculitic neuropathy. Muscle Nerve 29: 853-860.
35. Alves M, Cunha DA, Calegari VC. 2005. Nuclear factor-kappaB and advanced glycation end-products expression in lacrimal glands of aging rats. J Endocrinol 187: 159-166.
36. Devi A, Jolitha AB, Ishii N. 2006. Grape seed proanthocyanidin extract (GSPE) and antioxidant defense in the brain of adult rats. Med Sci Monit 12: BR124-129.
37. Ma L, Gao HQ, Li BY. 2007. Grape seed proanthocyanidin extracts inhibit vascular cell adhesion molecule expression induced by advanced glycation end products through activation of peroxisome proliferators-activated receptor gamma. J Cardiovasc Pharm 49: 293-298.
38. Durukan AH, Evereklioglu C, Hurmeric V. 2006. Ingestion of IH636 grape seed proanthocyanidin extract to prevent selenite-induced oxidative stress in experimental cataract. J Cataract Refr Surg 32: 1041-1045.
39. Shao ZH, Hsu CW, Chang WT. 2006. Cytotoxicity induced by grape seed proanthocyanidins: role of nitric oxide. Cell Biol Toxicol 22: 149-158.
40. Shao ZH, Vanden Hoek TL, Xie J. 2003. Grape seed proanthocyanidins induce pro-oxidant toxicity in cardiomyocytes. Cardiovasc Toxicol 3: 331-339.